Leerink Partners Starts Evommune Inc (EVMN) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
Cantor Fitzgerald Starts Evommune Inc (EVMN) at Overweight
December 1, 2025 6:09 AM ESTCantor Fitzgerald analyst Prakhar Agrawal initiates coverage on Evommune Inc (NYSE: EVMN) with a Overweight rating.
The analyst comments "We are very bullish on EVO756 for CSU given its differentiated mechanism, first-in-class potential, and positive data in CIndU, which meaningfully increases... More
Evercore ISI Starts Evommune Inc (EVMN) at Outperform
December 1, 2025 6:03 AM ESTEvercore ISI analyst Gavin Clark-Gartner initiates coverage on Evommune Inc (NYSE: EVMN) with a Outperform rating and a price target of $40.00.
The analyst comments "Evommune is an I&I (dermatology to start) focused company with a portfolio of assets. Lead indications are... More
William Blair Starts Evommune Inc (EVMN) at Outperform
December 1, 2025 5:06 AM ESTWilliam Blair analyst Matt Phipps initiates coverage on Evommune Inc (NYSE: EVMN) with a Outperform rating.
The analyst comments "We are initiating coverage of Evommune with an Outperform rating, based on the potential of the companys first-in-class MRGPRX2 inhibitor EVO756 in the... More
Morgan Stanley Starts Evommune Inc (EVMN) at Overweight
December 1, 2025 3:03 AM ESTMorgan Stanley analyst Judah Frommer initiates coverage on Evommune Inc (NYSE: EVMN) with a Overweight rating and a price target of $36.00.
The analyst comments: "Led by a management team with significant experience bringing anti-inflammatory therapies to patients (e.g., Ebglyss, Cimzia, Rezurock), Evommune is developing... More
